Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alzinova

0.42 SEK-0.47 %23/10 17:25
Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.47 %
+5.35 %
-37.40 %
-24.28 %
-47.29 %
-69.10 %
-78.51 %
-91.94 %
-93.91 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
133.85M SEK
Turnover
227.65K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
12/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-10-21 11:20

Alzinova slutför urvalet av sju kliniska prövningscenter i USA inför första deltagaren i fas IIa-studien ADVANCE

Alzinova
Press release2026-10-21 11:20

Alzinova finalises selection of seven US clinical sites as ADVANCE Phase 2a study moves toward first participant enrolment

Alzinova
Regulatory press release2026-10-20 07:30

Alzinovas styrelse beslutar om riktad emission av units till emissionsgarant i samband med den avslutade företrädesemissionen

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-10-20 07:30

Alzinova’s Board of Directors resolves on a directed issue of units to underwriters in connection with the completed rights issue

Alzinova
Press release2026-10-08 16:46

Redeye: Alzinova: Rights issue subscribed to 86.2%

Alzinova
Press release2026-10-08 16:05

Alzinova presenterar den senaste utvecklingen inom ALZ-101 och blodbaserad diagnostik på Redeye Neurology Day

Alzinova
Press release2026-10-08 16:05

Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day

Alzinova
Press release2026-10-08 08:00

DNB Carnegie Access: Alzinova: Rights issue completed

Alzinova
Regulatory press release2026-10-07 19:25

Alzinova offentliggör slutligt utfall i företrädesemissionen

Alzinova
Regulatory press release2026-10-07 19:25

Alzinova announces final outcome of the rights issue

Alzinova
Regulatory press release2026-10-06 17:46

Alzinova offentliggör preliminärt utfall i företrädesemissionen

Alzinova
Regulatory press release2026-10-06 17:46

Alzinova announces preliminary outcome of the rights issue

Alzinova
Regulatory press release2026-10-01 18:25

Alzinova breddar ägarbasen med ny institutionell investerare och huvudägaren tecknar hela sin pro rata andel i pågående företrädesemission

Alzinova
Regulatory press release2026-10-01 18:25

Alzinova broadens its shareholder base with a new institutional investor, while its principal shareholder subscribes for its full pro rata share in the ongoing rights issue

Alzinova
Regulatory press release2026-10-01 08:30

Sista dag för handel med uniträtter i Alzinovas företrädesemission

Alzinova
Regulatory press release2026-10-01 08:30

The last day of trading in unit rights in Alzinova’s rights issue

Alzinova
Press release2026-10-01 08:27

DNB Carnegie Access: Alzinova: Supportive early results for diagnostics programme

Alzinova
Regulatory press release2026-09-30 11:45

Alzinova slutför studie med Amsterdam UMC – resultat stödjer fortsatt utveckling och partnerdialoger inom blodbaserad Alzheimerdiagnostik

Alzinova
Regulatory press release2026-09-30 11:45

Alzinova completes study with Amsterdam UMC – results support continued development and partnership discussions in blood-based Alzheimer’s diagnostics

Alzinova
Press release2026-09-24 16:30

Alzinovas fas II-studie med ALZ-101 har accepterats för presentation vid internationell Alzheimerkongress

Alzinova